menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Phoenix Molecular Doses First Patient In Ph 2 Dauntless-1 Trial

    GLOBENEWSWIRE

    Fulvestrant API Reducing CO2 footprint by 3.4+ MT/kg

    PRESS RELEASE

    Relay Announces Updated Data for RLY-2608 + Fulvestrant

    GLOBENEWSWIRE

    Scorpion Presents STX-478 Data For Solid Tumors At ESMO Congress 2024

    BUSINESSWIRE

    Relay Therapeutics Announces Positive Data For RLY-2608

    GLOBENEWSWIRE

    Relay Therapeutics Announces Webcast For RLY-2608 Data Report

    GLOBENEWSWIRE

    Texas A&M Health and BurstIQ Partner to Revolutionize Clinical Genomics Research

    PR NEWSWIRE

    Roche’s PI3K inhibitor wins FDA priority review for breast cancer

    PHARMACEUTICAL TECHNOLOGY

    AZ’s Truqap plus Faslodex receives Japanese approval HR-positive breast cancer

    INDINPHARMAPOST

    Carrick Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib

    GLOBENEWSWIRE

    Roche`s inavolisib combo cuts breast cancer progression by 57%

    PRESS RELEASE

    eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin

    GLOBENEWSWIRE

    Astex Earns AstraZeneca Milestone for Truqap Approval

    CONTRACT PHARMA

    TRUQAP™ (capivasertib) plus fulvestrant approved in the US

    BUSINESSWIRE

    US FDA approves AstraZeneca`s breast cancer drug combination

    REUTERS

    NDA Submission Planned EA-114 in Metastatic Breast Cancer Following +ve Type C

    ONCLIVE

    Eugia`s Generic Fulvestrant Receives Approval in the U.S.

    FDA

    SONIA Trial Suggests Second-line Use May Be Optimal for CDK4/6 Inhibitors

    ONCOLIVE

    Capivasertib in combination with FASLODEX granted Priority Review in the US

    BUSINESSWIRE

    eFFECTOR reports interim data updates from cancer combo expansion cohort

    CLINICAL TRIALS ARENA

    Alembic Pharma gets USFDA nod for generic drug to treat breast cancer

    ECONOMICTIMES

    Alembic`s Generic Fulvestrant Receives Approval in the U.S.

    FDA

    Treadwell Announces Presentation Featuring Trial Update on CFI-402257

    BIONJ

    AstraZeneca hails positive findings in breast cancer drug trial

    PRESS RELEASE

    Pfizer backs $60M infusion into Carrick, teams up on breast cancer treatment

    ENDPTS

    Capivasertib plus FASLODEX improved progression-free survival vs. FASLODEX

    BUSINESSWIRE

    Camizestrant Improved Progression-free Survival Vs. FASLODEX in PII Trial

    BUSINESSWIRE

    Puma Announces Agreement with Takeda for the Development of Alisertib

    BUSINESSWIRE

    Sermonix Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant

    GLOBENEWSWIRE

    Enforcement Report - Week of August 24, 2022

    FDA

    NICE recommends Novartis’ Piqray therapy

    PHARMATIMES

    New Novartis data show Piqray effectiveness across key biomarkers

    EXPRESS PHARMA

    Laekna doses first subjects in Phase Ib/III breast cancer therapy trial

    CLINICALTRIALSARENA

    Roche hit with another key R&D setback as oral SERD flops in breast cancer

    FIERCEBIOTECH

    Jiangsu Hansoh Pharma`s Generic Fulvestrant Receives Approval in the U.S.

    FDA

    MHRA approves licence extension for Novartis’ targeted therapy for breast cancer

    PRESS RELEASE

    Context Therapeutics® & Wisconsin Oncology Network Announce 1st Patient PhTrial

    GLOBENEWSWIRE

    Cedilla adds $25M to series B to test two cancer drugs in trials

    FIERCEBIOTECH

    Menarini, chased by 3 Big Pharmas, records breast cancer win

    FIERCEBIOTECH

    Enforcement Report - Week of September 29, 2021

    FDA

    Carrick Presents Encouraging data for Samuraciclib in Combo with Fulvestrant

    GLOBENEWSWIRE

    Laekna Therapeutics bags NMPA nod for PIb/III study of afuresertib+fulvestrant

    PHARMABIZ

    FDA fast tracks breast cancer candidate samuraciclib

    PHARMA TIMES

    Dr. Reddy`s announces the launch of Fulvestrant Injection

    BUSINESS STANDARD

    Dr Reddys Lab SA`s Generic Fulvestrant Receives Approval in US

    FDA

    EU regulators approve Novartis` breast cancer combo

    PHARMA TIMES

    Novartis’ Kisquali bests AZ’ Faslodex in breast cancer trial

    PHARMA TIMES

    Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund

    PHARMA FILE

    Hbt lab`s Generic Fulvestrant Receives Approval in US

    FDA

    Novartis, Eli Lilly marquee positive survival data for CDK 4/6 franchises

    ENDPTS

    Pii to Manufacture FDA-Approved Hormone Therapy Injection Drug Product

    PR NEWSWIRE

    Mylan launches generic Faslodex inj in US market to treat advanced breast cancer

    PHARMABIZ

    Sagent Pharms`s Generic Fulvestrant Receives Approval in US

    FDA

    Glenmark Pharma`s Generic Fulvestrant Receives Approval in US

    FDA

    FDA Approves Generic Fulvestrant Injection for Advanced Breast Cancer

    PHARMACYTIMES

    Mylan Labs` Generic Fulvestrant Receives Approval in US

    FDA

    NICE U-turn for Kisqali in breast cancer

    PHARMATIMES

    Novartis’ Kisqali, trailing Lilly’s Verzenio, nabs limited NICE backing

    FIERCE PHARMA

    Darzalex, Ibrance among latest SMC decisions

    PHARMATIMES

    Copycats wanted: Pfizer, AZ and more under threat as China solicits generics

    FIERCE PHARMA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.